Promore Pharma AB (publ) Interim report January – March 2019
· Net sales amounted to MSEK 0.5 (0.1) MSEK · The operating loss for the period was 5.5 (loss 7.9) MSEK · Net loss was 5.5 MSEK (loss 7.9) MSEK, corresponding to a loss per share of SEK 0.27 (loss 0.39) · Cash flow from operating activities amounted to -4.4 (-8.5) MSEK · Cash and cash equivalents amounted to 26.6 (54.4) MSEK Significant events during the period January - March · Phase III trial with PXL01 modified and the number of clinics in the study expandedCEO statement Promore Pharma's most important task is to develop new products aiming to improve the